Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$86.72 USD

86.72
4,365,080

-0.64 (-0.73%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

    Should Value Investors Consider Gilead Sciences (GILD) Stock?

    Gilead Sciences (GILD) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.

      4 Biotech Stocks That Show Promise on Sustainable Growth

      Biotech sector is performing well in 2017 due to an increase in FDA approvals, new product sales ramp up, R&D success and innovation, strong clinical study results and continued strong performance of legacy products.

        Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock

        Gilead Sciences (GILD) needs Investors to pay close attention to the stock based on moves in the options market lately.

          3 Pharma/Biotech Sector Bargains for a Healthy Portfolio

          The biotech sector has turned around after its dismal performance in 2016 as uncertainty surrounding drug pricing control subsides. A few stocks are however still undervalued, which may gain going ahead.

            The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger

            The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger

              Arpita Dutt headshot

              5 Top-Ranked Biotech Stocks to Buy Right Now

              If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).

                Top Ranked Income Stocks to Buy for September 8th

                Here are four stocks with buy rank and strong income characteristics for investors to consider today, September 8th:

                  Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus

                  With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.

                    Mallinckrodt Down as District Court Invalidates Inomax Patents

                    Shares of Mallinckrodt plc (MNK) were down 12.3% after a U.S. District Court invalidated 11 patents covering its second-largest product Inomax.

                      Buy These 5 Large Caps on Extraordinary ROI Potential

                      Amid heightening tensions in the Korean Peninsula and hurricanes back home, let's take the safer route and invest for the long haul, using ROI as a barometer.

                        4 Biotech Stocks to Improve Your Portfolio's Health

                        The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016.

                          The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences

                          The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences

                            Arpita Dutt headshot

                            Biotech Stocks Back in Favor: Will the Rally Continue?

                            Interest in the biotech sector has picked up with the Gilead (GILD)-Kite acquisition announcement. Will the rally continue?

                              Valeant (VRX) Continues to Lose Ground: Can It Bounce Back?

                              Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services and woes do not end.

                                Ryan McQueeney headshot

                                Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods

                                On today's episode of the Zacks Friday Finish Line, Content Writer Ryan McQueeney and Editor Maddy Johnson take on this week's biggest stories, including Gilead's acquisition of Kite Pharma, the future of the CAR-T therapy industry, and Amazon's changes to Whole Foods stores.

                                  Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval

                                  Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL).

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update

                                    It's all about CAR-T stocks this week with Gilead (GILD) announcing its intention to acquire Kite Pharma for $11.9 billion and Novartis gaining FDA approval for the first CAR-T cell therapy.

                                      Ryan McQueeney headshot

                                      Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap

                                      The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world.

                                        Zacks.com featured highlights Broadcom, CBRE Group, Sandvik, Applied Materials and Gilead Sciences

                                        Zacks.com featured highlights Broadcom, CBRE Group, Sandvik, Applied Materials and Gilead Sciences

                                          Juno/Bluebird Hot Acquisition Targets After Kite/Gilead Deal

                                          Gilead's (GILD) $11.8 billion deal to buy Kite Pharma KITE) has made two other leading independent CAR-T developers, Juno and Bluebird Bio hot takeover targets.

                                            The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                            The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG

                                              Gilead (GILD) Up 2.1% Since Earnings Report: Can It Continue?

                                              Gilead (GILD) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.

                                                Kevin Cook headshot

                                                Indecision Won't Kill You, But It Will Take Your Money

                                                The pitfalls and powers of decision-making for traders and investors could be a model for everyone else.

                                                  Gilead to Fly High with Kite Pharma Acquisition for $11.9B

                                                  Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.